Overview

Niraparib/TTFields in GBM

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
NovoCure Ltd.
Tesaro, Inc.
Treatments:
Niraparib